Physician profile
Nitin Verma
NPI 1598872731
$1,531.14
in general payments reported to CMS, 2019-2025
11 companies · $81.75 in 2025
The $81.75 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $314 · 2020: $216 · 2021: $495 · 2022: $298 · 2023: $107 · 2024: $20.17 · 2025: $81.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $208.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $404.78 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $267.51 | 2020-2023 | Farxiga, Andexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.56 | 2019-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $156.59 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $140.37 | 2019-2022 | |
| Pfizer INC. | $116.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $82.65 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $80.59 | 2019 | |
| Biotronik INC. | $34.50 | 2022 | |
| Gilead Sciences, INC. | $14.64 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.